Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Amifostine is a cytoprotective agent mainly used in cancer therapies, in order to ameliorate the toxic effects of anticancer chemotherapy and radiotherapy. In the past years an intriguing number of applications of amifostine have been identified; one of these is bone marrow cells protection and stimulation. Amifostine was administered in seven patients with myelodysplastic syndromes, four males and 3 females aged between 67 and 78 years old, in order to estimate its efficacy in reducing the need for red blood cells transfusions. Two patients had RAEB, four RA and one RARS. The drug was administered in an outpatient basis in a dose of 300 mgr/m2, three times weekly for at least four weeks. We administered at the same time erythropoietin 10.000 U subcutaneously. All patients received daily supplementation of oral ferrum sulfate and folic acid. Three patients, a woman with RA and two men, one with RA and another with RAEB improved the levels of Hb beyond 12,0 gr/dl and did not receive blood transfusions after the second week of treatment. The drug was well tollerated without any side effects in all of the patients.
Tsiara
S N
SN
Hematology Unit, University Hospital of Ioannina, Greece.
Kapsali
H D
HD
Panteli
K
K
Christou
L
L
Bourantas
K L
KL
D000368:Aged; D004999:Amifostine / Q000627:therapeutic use*; D000753:Anemia, Refractory / Q000628:therapy; D000754:Anemia, Refractory, with Excess of Blasts / Q000628:therapy; D001803:Blood Transfusion; D001854:Bone Marrow Cells / Q000473:pathology; D019610:Cytoprotection; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000188:drug therapy / Q000628:therapy*; D010045:Outpatients; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D004999:Amifostine